Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (19 ops.)
Latest filing published 10 Aug 2026 for Spyre Therapeutics, Inc., €45k. Read the official filing
Filing timeline
BuySaleJeffrey W. Albers
Insider track record
Disclosed buys
0
Disclosed sells
19
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Jeffrey W. Albers: trading record in brief
This profile gathers the share dealings of Jeffrey W. Albers across 3 companies, led by Blueprint Medicines Corp, Kymera Therapeutics, Inc. and Spyre Therapeutics, Inc. The record holds 59 filings, for trades running from 12 May 2021 to 7 August 2026.
On the market, this insider has only sold: 19 sales, €7.6M in total. Besides market trades, the filings include 4 share grants and 34 option exercises. 2026 to date brings no purchases and 3 sales.
On 10 August 2026 came the latest disclosure, an option exercise for €45k in Spyre Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Jeffrey W. Albers
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations59 total
5,000 shares@ US$10.39Common StockSEC:0001636282-26-000102:0
5,000 shares@ US$104.47Common StockSEC:0001636282-26-000102:1
8,000 shares@ US$104.38Common StockSEC:0001636282-26-000102:2
10,000 shares@ US$104.68Common StockSEC:0001636282-26-000102:3
5,000 shares@ US$14.187.2% of flowCommon StockSEC:0001193125-25-311505:0
5,000 shares@ US$10.346.2% of flowCommon StockSEC:0001193125-25-238130:0
5,000 shares@ US$59.189835.3% of flowCommon StockSEC:0001193125-25-238130:1
5,777 sharesCommon StockSEC:0001104659-25-069377:0
3,902 shares@ US$128.125.6% of flowCommon StockSEC:0001415889-25-018086:0
6,349 shares@ US$10.347.4% of flowCommon StockSEC:0000950170-25-081198:0
5,000 shares@ US$36.051.9% of flowCommon StockSEC:0001415889-25-014862:0
4,350 shares@ US$101.024.7% of flowCommon StockSEC:0001415889-25-014862:1
650 shares@ US$101.930.7% of flowCommon StockSEC:0001415889-25-014862:2
5,766 shares@ US$88.806.2% of flowCommon StockSEC:0001415889-25-008211:0
7,500 shares@ US$36.053.2% of flowCommon StockSEC:0001415889-25-008112:0
10,000 shares@ US$36.054.5% of flowCommon StockSEC:0001415889-25-001989:0
5,000 shares@ US$36.052.3% of flowCommon StockSEC:0001415889-25-001507:0
15,000 shares@ US$36.056.7% of flowCommon StockSEC:0001415889-24-029971:0
5,000 shares@ US$36.052.2% of flowCommon StockSEC:0001415889-24-026594:0
5,000 shares@ US$102.006.1% of flowCommon StockSEC:0001415889-24-026594:1
6,700 shares@ US$36.763195.7% of flowCommon StockSEC:0001636282-24-000089:0
300 shares@ US$36.434.3% of flowCommon StockSEC:0001636282-24-000070:0
10,000 shares@ US$36.054.2% of flowCommon StockSEC:0001415889-24-023204:0
5,000 shares@ US$10.346.4% of flowCommon StockSEC:0000950170-24-100660:0
2,242 shares0Common StockSEC:0001415889-24-016987:0
25 of 59 declarations
